The combined inhibition of MCL-1 (using the MCL-1 inhibitor AZD5991) and BCL-2 (using venetoclax) significantly extended survival in mice bearing patient-derived xenografts from an AML patient who had developed resistance to venetoclax/decitabine. Here, BCL2 is linked to acute myeloid leukemia.